Making smart investment decisions in clinical research

Nick Bansback, Edward Keystone, James O'Dell, Ciaran S. Phibbs, Keri Hannagan, Mary Brophy, Aslam Anis

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275 , registered 29 November 2006

Original languageEnglish (US)
Article number590
JournalTrials
Volume16
Issue number1
DOIs
StatePublished - Dec 29 2015

Keywords

  • Economics
  • Randomized trials
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Making smart investment decisions in clinical research'. Together they form a unique fingerprint.

  • Cite this

    Bansback, N., Keystone, E., O'Dell, J., Phibbs, C. S., Hannagan, K., Brophy, M., & Anis, A. (2015). Making smart investment decisions in clinical research. Trials, 16(1), [590]. https://doi.org/10.1186/s13063-015-1123-1